Boston Scientific Corp.
Marlborough, MA 01752
Share:
Support Catheter comes in 0.018 and 0.035 in. dia. sizes.
Featuring FDA 510(k) clearance and CE Mark, both 0.035 and 0.018 in.- Rubicon™ Support Catheter- help physicians treat patients with peripheral arterial disease (PAD). Products are designed to assist with placement and support of guidewires used in peripheral vascular procedures to deliver stents and balloons to open blockages in legs and other peripheral arteries.
Read More »Boston Scientific Announces CE Mark and European Launch of Emerge(TM) PTCA Dilatation Catheter
Next-generation balloon catheter offers enhanced deliverability and expanded options for treating coronary artery lesions NATICK, Mass. - Boston Scientific Corporation (NYSE: BSX) announces CE Mark and European market launch of the Emerge(TM) PTCA[1] Dilatation Catheter. The Emerge Catheter is a next-generation pre-dilatation balloon catheter designed specifically to offer exceptional...
Read More »Maneuverable Sheath aids catheter introduction, placement.
Intended for use in electrophysiology (EP) procedures, Z Flex-270(TM) Steerable Sheath facilitates introduction and placement of diagnostic and therapeutic catheters within heart. Device is compatible with catheters up to 12 French and provides more than 270-
Read More »Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death
NATICK, Mass., Feb. 28 -- Boston Scientific Corporation (NYSE:BSX) today announced the first European implants of its COGNIS(TM) cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN(TM) implantable cardioverter defibrillator (ICD). Physicians began performing implants earlier this week. Forty implants have been performed in 14 hospitals in six countries. When choosing a high-energy...
Read More »Boston Scientific Receives CE Mark for TAXUS® Liberte(TM) Long Stent
Longest drug-eluting stent approved for the management of patients with clinically challenging coronary artery disease NATICK, Mass., and BARCELONA, Spain, May 24 /- Boston Scientific Corporation (NYSE:BSX) today announced that it has received CE Mark for its TAXUS® Liberte(TM) Long paclitaxel-eluting coronary stent system, allowing doctors to treat longer coronary artery lesions with a single...
Read More »Visualization System is used to examine bile duct.
SpyGlass(TM) Direct Visualization System for duodenoscope assisted cholangiopancreatoscopy enables direct visualization of all bile-duct quadrants. It provides 4-way steerability and irrigation channels as well as 1.2 mm working channel through which diagnostic and therapeutic devices can be used. Miniature 6,000-pixel fiber-optic probe that attaches to camera head is inserted through single-use...
Read More »Boston Scientific Announces First Use of PROMUS(TM) Everolimus-Eluting Stent System
Boston Scientific only company to offer two distinct drug-eluting stent platforms NATICK, Mass., Jan. 11 // -- Boston Scientific Corporation (NYSE:BSX) today announced the international launch and first implantation of the PROMUS(TM) Everolimus-Eluting Stent, making Boston Scientific the only company to offer two distinct drug-eluting stent (DES) platforms. PROMUS is a private-labeled XIENCE(TM)...
Read More »Boston Scientific and GE Healthcare Announce the First Integration of Remote Device Information Direct to Electronic Medical Records
NATICK, Mass., Nov. 9 / - Boston Scientific Corporation (NYSE:BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's LATITUDE® 2.0 next-generation software with LATITUDE remote data integration capabilities. LATITUDE Patient Management is the first and only remote monitoring system to provide clinicians with direct device data integration capability into...
Read More »Boston Scientific Receives CE Mark for Artisan(TM) Surgical Lead for Use with Neurostimulation Device to Treat Chronic Pain
Innovative Technology Makes Precision(TM) Spinal Cord Stimulator Accessible to More Patients NATICK, Mass., Nov. 3 // -- Boston Scientific Corporation (NYSE:BSX) today announced that it has received the European CE Mark for its new Artisan(TM) 2x8 Surgical Lead for use with the Precision(TM) Spinal Cord Stimulation (SCS) System. This surgical or paddle lead potentially expands the application of...
Read More »Defibrillators promote fine-tune heart synchronization.
CONTAK RENEWAL-®, RENEWAL 3, and RENEWAL 3 RF cardiac resynchronization therapy defibrillators (CRT-D) are available with FDA-approved Left Ventricular (LV) Offset software, which lets physicians adjust delay between right and left ventricular pacing. Able to operate on ZOOM-® LATITUDE(TM) programmer, LV Offset feature can be enabled during routine, in-clinic patient visit.
Read More »Boston Scientific Announces Acquisition of The LumenR™ Tissue Retractor System
Technology to Improve Management of Gastrointestinal Diseases MARLBOROUGH, Mass., Nov. 3, 2016 - Boston Scientific (NYSE: BSX) today announced the acquisition of the LumenR™ Tissue Retractor System from LumenR LLC, a privately held Newark, California based company. The LumenR Tissue Retractor System is currently in development for use during endoscopic resection of lesions in the colon,...
Read More »Boston Scientific Announces Additional Investment and Right to Acquire MValve Technologies
Investment continues alliance for percutaneous mitral valve replacement established in 2012 MARLBOROUGH, Mass. and HERZLIYA, Israel - Boston Scientific Corporation (NYSE: BSX) today announced that it has closed on an additional round of financing with MValve Technologies Ltd., a developer of a percutaneous mitral valve replacement system, designed to work with the Boston Scientific LOTUS™...
Read More »Boston Scientific Closes Acquisition of the American Medical Systems Male Urology Portfolio
MARLBOROUGH, Mass. - Boston Scientific Corporation (NYSE: BSX) has closed on the previously announced agreement with Endo International plc (NASDAQ: ENDP) (TSX: ENL) to purchase American Medical Systems' (AMS) Men's Health and Prostate Health businesses, for $1.6 billion in up-front cash and a potential additional $50 million milestone based on 2016 sales. The acquisition positions Boston...
Read More »Boston Scientific Agrees to Acquire Xlumena
MARLBOROUGH, Mass. and MOUNTAIN VIEW, Calif. –- Boston Scientific Corporation (NYSE: BSX) announces that it has signed a definitive agreement to acquire Xlumena, Inc., a venture-backed medical device company that develops, manufactures and sells minimally invasive devices for Endoscopic Ultrasound (EUS) guided transluminal drainage of targeted areas within the gastrointestinal tract. The deal...
Read More »Support Catheter comes in 0.018 and 0.035 in. dia. sizes.
Featuring FDA 510(k) clearance and CE Mark, both 0.035 and 0.018 in.- Rubicon™ Support Catheter- help physicians treat patients with peripheral arterial disease (PAD). Products are designed to assist with placement and support of guidewires used in peripheral vascular procedures to deliver stents and balloons to open blockages in legs and other peripheral arteries.
Read More »Boston Scientific Announces CE Mark and European Launch of Emerge(TM) PTCA Dilatation Catheter
Next-generation balloon catheter offers enhanced deliverability and expanded options for treating coronary artery lesions NATICK, Mass. - Boston Scientific Corporation (NYSE: BSX) announces CE Mark and European market launch of the Emerge(TM) PTCA[1] Dilatation Catheter. The Emerge Catheter is a next-generation pre-dilatation balloon catheter designed specifically to offer exceptional...
Read More »Maneuverable Sheath aids catheter introduction, placement.
Intended for use in electrophysiology (EP) procedures, Z Flex-270(TM) Steerable Sheath facilitates introduction and placement of diagnostic and therapeutic catheters within heart. Device is compatible with catheters up to 12 French and provides more than 270-
Read More »Boston Scientific Announces Its ACC 2011 Schedule
Clinical presentations to include 12-month data on PROMUS Element(TM) Platinum Chromium Stent NATICK, Mass., March 29, 2011 - Boston Scientific Corporation (NYSE: BSX) today announced its clinical trial news and events schedule at the 60th Annual Scientific Session of the American College of Cardiology/i2 Summit, April 2-5, 2011 in New Orleans. Twelve-month results from the PLATINUM Workhorse...
Read More »Boston Scientific to Webcast Analyst Event
NATICK, Mass., March 22, 2011 - Boston Scientific Corporation (NYSE: BSX) today announced that it will hold an analyst event on April 4, 2011 at the 60th Annual Scientific Session of the American College of Cardiology/i2 Summit in New Orleans. The Company will provide an update on its Cardiology, Rhythm and Vascular (CRV) Group initiatives involving coronary stent and structural heart...
Read More »Boston Scientific to Present at Barclays Capital 2011 Global Healthcare Conference
NATICK, Mass., March 8, 2011 -- Boston Scientific Corporation (NYSE: BSX) is scheduled to present at the Barclays Capital 2011 Global Healthcare Conference in Miami. Jeff Capello, Executive Vice President and Chief Financial Officer, will make a 25-minute presentation on Tuesday, March 15, 2011. The presentation is scheduled to begin at 8:30 a.m. ET. A live webcast of the presentation will be...
Read More »